Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Butler et al., The Lancet, doi:10.1016/S0140-6736(22)02597-1 (preprint 10/6/2022)
https://c19early.org/butler2.html